BCL2 and non-small cell lung carcinoma: As far as the standalone versus combination therapy is concerned, though we have not assessed the potential of FD-895/Pladienolide- B in combination with an inhibitor of BCL-2 family members, but at the same time there are studies where a combination of splicing inhibitors meayamycin B with ABT-737 (Bcl-xL inhibitor) led to apoptosis in non-small cell lung cancer cell lines (A549 and H1299) [83].